Influence of treatment on the maturation of the somesthetic pathway in infants with primary congenital hypothyroidism during the first year of life

To assess the influence of treatment on the development of the somesthetic pathway in infants with congenital hypothyroidism receiving early treatment, median nerve somatosensory evoked potentials were measured during the 1st y of life. Twenty-nine infants were studied with six to seven somatosensor...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatric research 1993-07, Vol.34 (1), p.73-78
Hauptverfasser: BONGERS-SCHOKKING, J. J, COLON, E. J, MULDER, P. G. H, HOOGLAND, R. A, DE GROOT, C. J, VAN DEN BRANDE, J. L
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 78
container_issue 1
container_start_page 73
container_title Pediatric research
container_volume 34
creator BONGERS-SCHOKKING, J. J
COLON, E. J
MULDER, P. G. H
HOOGLAND, R. A
DE GROOT, C. J
VAN DEN BRANDE, J. L
description To assess the influence of treatment on the development of the somesthetic pathway in infants with congenital hypothyroidism receiving early treatment, median nerve somatosensory evoked potentials were measured during the 1st y of life. Twenty-nine infants were studied with six to seven somatosensory evoked potential tests per infant. The cervical latency (N13) divided by arm length and the first (N19) and second (N32) cephalic latencies as well as N13-N32 latency were measured. At diagnosis, all components showed a small but significant delay, which was not related to thyroxine (T4) levels before treatment. During treatment, T4 ranged from 50 to 290 nmol/L. At 12 mo, the cervical latency divided by arm length had normalized, whereas N19 and N13-N32 were more abnormal than at diagnosis. For N19, these abnormalities were related to a slow initial rise of T4 (< or = 100 nmol/L after 1 wk of treatment) and the initial N19 values. Abnormal N13-N32 values were associated with high T4 values during treatment (> 200 nmol/L) and the type of congenital hypothyroidism (partial or total deficiency in T4 production). Induction of therapy with l-triiodothyronine rather than l-thyroxine and the occurrence of low T4 values (< 100 nmol/L) after the 4th wk of therapy had no such effect. Our data suggest that, for normal CNS development, euthyroidism should be reached as soon as possible by adequate induction therapy. Thereafter, T4 supplementation should be strictly dosed, keeping the serum T4 values within narrow limits around the mean normal for age, because overtreatment, like initial undertreatment, may lead to CNS abnormalities at the end of the first year.
doi_str_mv 10.1203/00006450-199307000-00017
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_75902679</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>75902679</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3047-f8e84f8700ffb23500c47d1423d1cf26ff4208d8db63ee746526fb771015713d3</originalsourceid><addsrcrecordid>eNo9UctOxSAQJUaj18cnmLAw7qpQaKFLY3wlJm503XDpYDEtXIHG9Dv8YblaL4HAzDkzw8lBCFNyRUvCrkleNa9IQZuGEZGjIh8q9tCKViwHnIt9tCKE0YI1jTxCxzF-ZAavJD9Eh5JVNSnZCn0_OTNM4DRgb3AKoNIILmHvcOoBjypNQSWbwy2cM9GPEPMjWY03KvVfasbW5W2USxF_2dTjTbCjCjPW3r2Ds0kNuJ83PvVz8LazccTdFKx7_21obIgJz6DCdsRgDZyiA6OGCGfLfYLe7u9ebx-L55eHp9ub50IzwkVhJEhuZBZvzLpkFSGai47yknVUm7I2hpdEdrJb1wxA8LrKubUQlNBKUNaxE3T513cT_OeUVbWjjRqGQTnwU2xF1ZCyFk0myj-iDj7GAKZdFLaUtFs_2n8_2p0f7a8fufR8mTGtR-h2hYsBGb9YcBW1GkxQTtu4o3FJ8gca9gPonJVD</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>75902679</pqid></control><display><type>article</type><title>Influence of treatment on the maturation of the somesthetic pathway in infants with primary congenital hypothyroidism during the first year of life</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Complete</source><source>Springer Nature - Complete Springer Journals</source><source>Alma/SFX Local Collection</source><creator>BONGERS-SCHOKKING, J. J ; COLON, E. J ; MULDER, P. G. H ; HOOGLAND, R. A ; DE GROOT, C. J ; VAN DEN BRANDE, J. L</creator><creatorcontrib>BONGERS-SCHOKKING, J. J ; COLON, E. J ; MULDER, P. G. H ; HOOGLAND, R. A ; DE GROOT, C. J ; VAN DEN BRANDE, J. L</creatorcontrib><description>To assess the influence of treatment on the development of the somesthetic pathway in infants with congenital hypothyroidism receiving early treatment, median nerve somatosensory evoked potentials were measured during the 1st y of life. Twenty-nine infants were studied with six to seven somatosensory evoked potential tests per infant. The cervical latency (N13) divided by arm length and the first (N19) and second (N32) cephalic latencies as well as N13-N32 latency were measured. At diagnosis, all components showed a small but significant delay, which was not related to thyroxine (T4) levels before treatment. During treatment, T4 ranged from 50 to 290 nmol/L. At 12 mo, the cervical latency divided by arm length had normalized, whereas N19 and N13-N32 were more abnormal than at diagnosis. For N19, these abnormalities were related to a slow initial rise of T4 (&lt; or = 100 nmol/L after 1 wk of treatment) and the initial N19 values. Abnormal N13-N32 values were associated with high T4 values during treatment (&gt; 200 nmol/L) and the type of congenital hypothyroidism (partial or total deficiency in T4 production). Induction of therapy with l-triiodothyronine rather than l-thyroxine and the occurrence of low T4 values (&lt; 100 nmol/L) after the 4th wk of therapy had no such effect. Our data suggest that, for normal CNS development, euthyroidism should be reached as soon as possible by adequate induction therapy. Thereafter, T4 supplementation should be strictly dosed, keeping the serum T4 values within narrow limits around the mean normal for age, because overtreatment, like initial undertreatment, may lead to CNS abnormalities at the end of the first year.</description><identifier>ISSN: 0031-3998</identifier><identifier>EISSN: 1530-0447</identifier><identifier>DOI: 10.1203/00006450-199307000-00017</identifier><identifier>PMID: 8356023</identifier><identifier>CODEN: PEREBL</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams &amp; Wilkins</publisher><subject>Biological and medical sciences ; Central Nervous System - growth &amp; development ; Central Nervous System - physiopathology ; Congenital Hypothyroidism ; Evoked Potentials, Somatosensory ; Female ; Hormones. Endocrine system ; Humans ; Hypothyroidism - drug therapy ; Hypothyroidism - physiopathology ; Infant ; Infant, Newborn ; Male ; Medical sciences ; Pharmacology. Drug treatments ; Thyrotropin - blood ; Thyroxine - blood ; Thyroxine - therapeutic use ; Triiodothyronine - therapeutic use</subject><ispartof>Pediatric research, 1993-07, Vol.34 (1), p.73-78</ispartof><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3047-f8e84f8700ffb23500c47d1423d1cf26ff4208d8db63ee746526fb771015713d3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=4806799$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8356023$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BONGERS-SCHOKKING, J. J</creatorcontrib><creatorcontrib>COLON, E. J</creatorcontrib><creatorcontrib>MULDER, P. G. H</creatorcontrib><creatorcontrib>HOOGLAND, R. A</creatorcontrib><creatorcontrib>DE GROOT, C. J</creatorcontrib><creatorcontrib>VAN DEN BRANDE, J. L</creatorcontrib><title>Influence of treatment on the maturation of the somesthetic pathway in infants with primary congenital hypothyroidism during the first year of life</title><title>Pediatric research</title><addtitle>Pediatr Res</addtitle><description>To assess the influence of treatment on the development of the somesthetic pathway in infants with congenital hypothyroidism receiving early treatment, median nerve somatosensory evoked potentials were measured during the 1st y of life. Twenty-nine infants were studied with six to seven somatosensory evoked potential tests per infant. The cervical latency (N13) divided by arm length and the first (N19) and second (N32) cephalic latencies as well as N13-N32 latency were measured. At diagnosis, all components showed a small but significant delay, which was not related to thyroxine (T4) levels before treatment. During treatment, T4 ranged from 50 to 290 nmol/L. At 12 mo, the cervical latency divided by arm length had normalized, whereas N19 and N13-N32 were more abnormal than at diagnosis. For N19, these abnormalities were related to a slow initial rise of T4 (&lt; or = 100 nmol/L after 1 wk of treatment) and the initial N19 values. Abnormal N13-N32 values were associated with high T4 values during treatment (&gt; 200 nmol/L) and the type of congenital hypothyroidism (partial or total deficiency in T4 production). Induction of therapy with l-triiodothyronine rather than l-thyroxine and the occurrence of low T4 values (&lt; 100 nmol/L) after the 4th wk of therapy had no such effect. Our data suggest that, for normal CNS development, euthyroidism should be reached as soon as possible by adequate induction therapy. Thereafter, T4 supplementation should be strictly dosed, keeping the serum T4 values within narrow limits around the mean normal for age, because overtreatment, like initial undertreatment, may lead to CNS abnormalities at the end of the first year.</description><subject>Biological and medical sciences</subject><subject>Central Nervous System - growth &amp; development</subject><subject>Central Nervous System - physiopathology</subject><subject>Congenital Hypothyroidism</subject><subject>Evoked Potentials, Somatosensory</subject><subject>Female</subject><subject>Hormones. Endocrine system</subject><subject>Humans</subject><subject>Hypothyroidism - drug therapy</subject><subject>Hypothyroidism - physiopathology</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Thyrotropin - blood</subject><subject>Thyroxine - blood</subject><subject>Thyroxine - therapeutic use</subject><subject>Triiodothyronine - therapeutic use</subject><issn>0031-3998</issn><issn>1530-0447</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9UctOxSAQJUaj18cnmLAw7qpQaKFLY3wlJm503XDpYDEtXIHG9Dv8YblaL4HAzDkzw8lBCFNyRUvCrkleNa9IQZuGEZGjIh8q9tCKViwHnIt9tCKE0YI1jTxCxzF-ZAavJD9Eh5JVNSnZCn0_OTNM4DRgb3AKoNIILmHvcOoBjypNQSWbwy2cM9GPEPMjWY03KvVfasbW5W2USxF_2dTjTbCjCjPW3r2Ds0kNuJ83PvVz8LazccTdFKx7_21obIgJz6DCdsRgDZyiA6OGCGfLfYLe7u9ebx-L55eHp9ub50IzwkVhJEhuZBZvzLpkFSGai47yknVUm7I2hpdEdrJb1wxA8LrKubUQlNBKUNaxE3T513cT_OeUVbWjjRqGQTnwU2xF1ZCyFk0myj-iDj7GAKZdFLaUtFs_2n8_2p0f7a8fufR8mTGtR-h2hYsBGb9YcBW1GkxQTtu4o3FJ8gca9gPonJVD</recordid><startdate>199307</startdate><enddate>199307</enddate><creator>BONGERS-SCHOKKING, J. J</creator><creator>COLON, E. J</creator><creator>MULDER, P. G. H</creator><creator>HOOGLAND, R. A</creator><creator>DE GROOT, C. J</creator><creator>VAN DEN BRANDE, J. L</creator><general>Lippincott Williams &amp; Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199307</creationdate><title>Influence of treatment on the maturation of the somesthetic pathway in infants with primary congenital hypothyroidism during the first year of life</title><author>BONGERS-SCHOKKING, J. J ; COLON, E. J ; MULDER, P. G. H ; HOOGLAND, R. A ; DE GROOT, C. J ; VAN DEN BRANDE, J. L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3047-f8e84f8700ffb23500c47d1423d1cf26ff4208d8db63ee746526fb771015713d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Biological and medical sciences</topic><topic>Central Nervous System - growth &amp; development</topic><topic>Central Nervous System - physiopathology</topic><topic>Congenital Hypothyroidism</topic><topic>Evoked Potentials, Somatosensory</topic><topic>Female</topic><topic>Hormones. Endocrine system</topic><topic>Humans</topic><topic>Hypothyroidism - drug therapy</topic><topic>Hypothyroidism - physiopathology</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Thyrotropin - blood</topic><topic>Thyroxine - blood</topic><topic>Thyroxine - therapeutic use</topic><topic>Triiodothyronine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BONGERS-SCHOKKING, J. J</creatorcontrib><creatorcontrib>COLON, E. J</creatorcontrib><creatorcontrib>MULDER, P. G. H</creatorcontrib><creatorcontrib>HOOGLAND, R. A</creatorcontrib><creatorcontrib>DE GROOT, C. J</creatorcontrib><creatorcontrib>VAN DEN BRANDE, J. L</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BONGERS-SCHOKKING, J. J</au><au>COLON, E. J</au><au>MULDER, P. G. H</au><au>HOOGLAND, R. A</au><au>DE GROOT, C. J</au><au>VAN DEN BRANDE, J. L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Influence of treatment on the maturation of the somesthetic pathway in infants with primary congenital hypothyroidism during the first year of life</atitle><jtitle>Pediatric research</jtitle><addtitle>Pediatr Res</addtitle><date>1993-07</date><risdate>1993</risdate><volume>34</volume><issue>1</issue><spage>73</spage><epage>78</epage><pages>73-78</pages><issn>0031-3998</issn><eissn>1530-0447</eissn><coden>PEREBL</coden><abstract>To assess the influence of treatment on the development of the somesthetic pathway in infants with congenital hypothyroidism receiving early treatment, median nerve somatosensory evoked potentials were measured during the 1st y of life. Twenty-nine infants were studied with six to seven somatosensory evoked potential tests per infant. The cervical latency (N13) divided by arm length and the first (N19) and second (N32) cephalic latencies as well as N13-N32 latency were measured. At diagnosis, all components showed a small but significant delay, which was not related to thyroxine (T4) levels before treatment. During treatment, T4 ranged from 50 to 290 nmol/L. At 12 mo, the cervical latency divided by arm length had normalized, whereas N19 and N13-N32 were more abnormal than at diagnosis. For N19, these abnormalities were related to a slow initial rise of T4 (&lt; or = 100 nmol/L after 1 wk of treatment) and the initial N19 values. Abnormal N13-N32 values were associated with high T4 values during treatment (&gt; 200 nmol/L) and the type of congenital hypothyroidism (partial or total deficiency in T4 production). Induction of therapy with l-triiodothyronine rather than l-thyroxine and the occurrence of low T4 values (&lt; 100 nmol/L) after the 4th wk of therapy had no such effect. Our data suggest that, for normal CNS development, euthyroidism should be reached as soon as possible by adequate induction therapy. Thereafter, T4 supplementation should be strictly dosed, keeping the serum T4 values within narrow limits around the mean normal for age, because overtreatment, like initial undertreatment, may lead to CNS abnormalities at the end of the first year.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams &amp; Wilkins</pub><pmid>8356023</pmid><doi>10.1203/00006450-199307000-00017</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0031-3998
ispartof Pediatric research, 1993-07, Vol.34 (1), p.73-78
issn 0031-3998
1530-0447
language eng
recordid cdi_proquest_miscellaneous_75902679
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Complete; Springer Nature - Complete Springer Journals; Alma/SFX Local Collection
subjects Biological and medical sciences
Central Nervous System - growth & development
Central Nervous System - physiopathology
Congenital Hypothyroidism
Evoked Potentials, Somatosensory
Female
Hormones. Endocrine system
Humans
Hypothyroidism - drug therapy
Hypothyroidism - physiopathology
Infant
Infant, Newborn
Male
Medical sciences
Pharmacology. Drug treatments
Thyrotropin - blood
Thyroxine - blood
Thyroxine - therapeutic use
Triiodothyronine - therapeutic use
title Influence of treatment on the maturation of the somesthetic pathway in infants with primary congenital hypothyroidism during the first year of life
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T00%3A09%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Influence%20of%20treatment%20on%20the%20maturation%20of%20the%20somesthetic%20pathway%20in%20infants%20with%20primary%20congenital%20hypothyroidism%20during%20the%20first%20year%20of%20life&rft.jtitle=Pediatric%20research&rft.au=BONGERS-SCHOKKING,%20J.%20J&rft.date=1993-07&rft.volume=34&rft.issue=1&rft.spage=73&rft.epage=78&rft.pages=73-78&rft.issn=0031-3998&rft.eissn=1530-0447&rft.coden=PEREBL&rft_id=info:doi/10.1203/00006450-199307000-00017&rft_dat=%3Cproquest_cross%3E75902679%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=75902679&rft_id=info:pmid/8356023&rfr_iscdi=true